| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/19/2000 | EP0993483A1 Conjugate of polyethylene glycol and chitosan |
| 04/19/2000 | EP0993305A2 Composition for enhanced uptake of polar drugs from mucosal surfaces |
| 04/19/2000 | EP0993304A1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 04/19/2000 | CN1251045A Gel delivery vehicles for anticellular proliferative agent |
| 04/19/2000 | CN1250669A Ion composite type water-soluble pharmaceutical compositions, and use thereof |
| 04/19/2000 | CN1250652A Compositions contg. benzoxazinone and nucleoside like materials |
| 04/19/2000 | CN1051453C Compositions of clindamycin and benzoyl peroxide for acne treatment |
| 04/18/2000 | USRE36665 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 04/18/2000 | US6051691 Amino acid sequence of protein; for screening bactericides and bacteristats especially targeted to streptococci |
| 04/18/2000 | US6051602 Methods for regulating skin appearance |
| 04/18/2000 | US6051594 Orally administering a formulation of the vasodilator phentolamine to the blood circulation |
| 04/18/2000 | US6051573 Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists |
| 04/18/2000 | US6051566 Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation |
| 04/18/2000 | US6051565 Farnesyl-protein transferase inhibitors |
| 04/18/2000 | US6051563 Methods for the administration of amifostine and related compounds |
| 04/18/2000 | US6051400 An expression system comprising of a polynucleotide encoding a protein; therapy and diagnosis of kidney diseases, cardiovascular disorders, strokes, alzheimer's disease; anticarcinogenic agents and antiinflammatory agents |
| 04/18/2000 | US6051227 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 04/18/2000 | US6051221 BRK protein tyrosine kinase and encoding nucleic acid |
| 04/18/2000 | US6051217 Administering to patient with hematopoietic or immunodeficiency |
| 04/15/2000 | CA2284853A1 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |
| 04/13/2000 | WO2000020867A1 A novel ret-independent signaling pathway for gdnf |
| 04/13/2000 | WO2000020634A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| 04/13/2000 | WO2000020625A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 04/13/2000 | WO2000020621A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | WO2000020603A1 Altered fatty acid biosynthesis in insect cells using delta five desaturase |
| 04/13/2000 | WO2000020602A2 Delta 6 and delta 12 desaturases and modified fatty acid biosynthesis and products produced therefrom |
| 04/13/2000 | WO2000020590A2 G-protein coupled receptor proteins |
| 04/13/2000 | WO2000020587A2 Cancer associated antigens and uses therefor |
| 04/13/2000 | WO2000020581A1 Mage-a3 peptides presented by hla class ii molecules |
| 04/13/2000 | WO2000020576A2 Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| 04/13/2000 | WO2000020575A1 Pollinosis-associated gene |
| 04/13/2000 | WO2000020458A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 04/13/2000 | WO2000020457A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 04/13/2000 | WO2000020446A2 Bax-mediated apoptosis modulating reagents and methods |
| 04/13/2000 | WO2000020398A1 Biphenylene lactams as prostaglandin receptor ligands |
| 04/13/2000 | WO2000020371A1 Prostaglandin receptor ligands |
| 04/13/2000 | WO2000020357A2 Chemical constructs |
| 04/13/2000 | WO2000020041A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | WO2000020037A1 A novel component in the hedgehog signalling pathway |
| 04/13/2000 | WO2000020034A1 Agents for retarding change of hormone-dependent cancer into hormone-independent cancer |
| 04/13/2000 | WO2000020031A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | WO2000020025A2 Akt compositions for enhancing survival of cells |
| 04/13/2000 | WO2000020024A2 Methods for the treatment of non-thyroid disorders |
| 04/13/2000 | WO2000020020A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 04/13/2000 | WO2000020011A1 Isolated dna encoding human h3 histamine receptor |
| 04/13/2000 | WO2000020007A1 Method and compositions for increasing bone mass |
| 04/13/2000 | WO2000020001A1 Mglur5 antagonists for the treatment of pain and anxiety |
| 04/13/2000 | WO2000019998A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
| 04/13/2000 | WO2000019991A1 Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung |
| 04/13/2000 | WO2000019990A2 Rar antagonists as male anti-fertility agents |
| 04/13/2000 | WO2000019987A1 Mucosal originated drug delivery systems and animal applications |
| 04/13/2000 | WO2000019978A2 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 04/13/2000 | WO2000019976A2 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them |
| 04/13/2000 | WO2000019883A2 Compositions and methods of disease diagnosis and therapy |
| 04/13/2000 | WO2000019823A1 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
| 04/13/2000 | WO2000003015A3 Human transport protein homologs |
| 04/13/2000 | WO2000001415A3 Use of inhibitors of protein kinase c epsilon to treat pain |
| 04/13/2000 | WO2000000634A3 METHODS OF INHIBITING $i(HELICOBACTER PYLORI) |
| 04/13/2000 | WO1999065462A3 Use of aminosterol derivatives as chloride ionphores |
| 04/13/2000 | WO1999063935A3 Rapid opioid detoxification therapy and anti-readdiction therapy |
| 04/13/2000 | WO1999053897A3 Topical formulation comprising poloxamers and further microbicides, and an applicator |
| 04/13/2000 | CA2354544A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| 04/13/2000 | CA2346765A1 Compositions and methods of disease diagnosis and therapy |
| 04/13/2000 | CA2346695A1 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
| 04/13/2000 | CA2346687A1 Use of rar antagonists or inverse agonists as male anit-fertility agents |
| 04/13/2000 | CA2346459A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 04/13/2000 | CA2346456A1 Method and compositions for increasing bone mass |
| 04/13/2000 | CA2346445A1 Biphenylene lactams as prostaglandin receptor ligands |
| 04/13/2000 | CA2346443A1 Prostaglandin receptor ligands |
| 04/13/2000 | CA2346339A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 04/13/2000 | CA2346333A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
| 04/13/2000 | CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | CA2346070A1 Bax-mediated apoptosis modulating reagents and methods |
| 04/13/2000 | CA2346048A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | CA2346029A1 Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung |
| 04/13/2000 | CA2345881A1 Bone marrow-derived serum proteins |
| 04/13/2000 | CA2345808A1 Mucosal originated drug delivery systems and animal applications |
| 04/13/2000 | CA2345642A1 Methods for the treatment of non-thyroid disorders |
| 04/13/2000 | CA2345477A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 04/13/2000 | CA2345408A1 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | CA2345240A1 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them |
| 04/13/2000 | CA2345213A1 Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer |
| 04/13/2000 | CA2345137A1 Mglur5 antagonists for the treatment of pain and anxiety |
| 04/13/2000 | CA2345045A1 G-protein coupled receptor proteins |
| 04/13/2000 | CA2344995A1 Cancer associated antigens and uses therefor |
| 04/13/2000 | CA2344973A1 Oxidoreductase molecules |
| 04/13/2000 | CA2335391A1 Akt compositions for enhancing survival of cells |
| 04/13/2000 | CA2285818A1 Composition to enhance skin permeation of topical skin agents |
| 04/12/2000 | EP0992492A1 Small molecule inhibitors of rotamase enzyme activity |
| 04/12/2000 | EP0992238A1 Use of triclosan for preventing and treating mucosal and dermal conditions |
| 04/12/2000 | EP0991758A1 Smad6 and uses thereof |
| 04/12/2000 | EP0991659A1 Peptides and compounds that bind to the il-5 receptor |
| 04/12/2000 | EP0991424A1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 04/12/2000 | EP0991422A1 Modulating epithelial-mesenchymal interactions |
| 04/12/2000 | EP0991421A2 Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease |
| 04/12/2000 | EP0991420A1 Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands |
| 04/12/2000 | EP0991419A1 Treatment of infertility with leptin receptor ligands |
| 04/12/2000 | EP0991414A1 Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| 04/12/2000 | EP0991319A2 Treatment for diabetes |
| 04/12/2000 | CN1250376A Treatment of infarcts through inhibition of NF-KAPPAB |